Navigation Links
Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Date:10/23/2008

Dr. Jonathan Stamler Has Authored A New Understanding Of Heart Failure

LA JOLLA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska") announced today that Jonathan S. Stamler, M.D., has joined the company as an exclusive scientific consultant to advise on the clinical development of CDP-1050, a drug candidate for the treatment of heart failure.

Dr. Stamler is the George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University. He has conducted scientific studies that establish a ubiquitous role for nitric oxide in the regulation of protein function. Dr. Stamler's research supports the hypothesis that dysregulated nitric oxide signaling commonly contributes to human disease including heart failure, arrhythmia, respiratory diseases, and cancer.

Dr. Stamler's notable achievements include the discovery that nitric oxide is transported by hemoglobin in red blood cells and has a pivotal role in control of blood flow; the mechanism by which nitroglycerin alleviates chest pain in angina patients and the cause of nitrate tolerance in these same patients; and the finding that depletion of nitric oxide from stored red blood cells may be the underlying cause for the undesired outcomes arising from blood transfusions such as higher incidence of heart attack, heart failure, stroke and even death. He has also discovered a general mechanism by which protein function is regulated (termed S-nitrosylation), malfunction of which contributes to many human diseases.

Dr. Stamler has conducted research on nitric oxide-redox imbalance in the failing heart and cardiovascular system. This research has yielded key evidence that altered production and distribution of reactive oxygen and nitric oxide species damages the cardiovascular system and contributes to the poor pumping capacity that characterizes the failing heart.

Although not fu
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
2. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
3. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
6. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
7. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
8. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
9. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
10. Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV
11. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... of the top 10 pharmaceutical giants use Datafarm ...h Canada. Datafarm’s announcement comes on t...ual Meeting where Health Canada stated that, effec...rid eCTD regulatory submissions for New Drug Submi...request. , Marlborough, M...
(Date:11/9/2009)...PRNewswire/ -- Following the provision of clinical...istration (FDA), privately,owned UK company Daval ...nal.com ) has been informed that its innovative,an...an Orphan-Drug,designation for the treatment of Am... also known as Lou Gehrig,s disease, is the most c...
(Date:11/8/2009)... Nov. 5, 2009 Complete Genomics, a third-generat...ed publication of a report in the journal Science...rm, including analysis of sequence data from three...these three genomes sequenced on the proof-of-prin...r 87x coverage to $1,726 for 45x coverage for the ...
(Date:11/6/2009)...ire-FirstCall/ - Microbix Biosystems Inc. (the "Co...orm 52-109F1 Certification of Annual Filings of Wi...s Long, the Chief Financial Officer (the "Officer,...ion with the annual audited financial statements f...mpany initially filed the annual financial stateme...
Breaking Biology Technology:Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2
...h 25 InNexus Biotechnology Inc., (OTC Bulletin Bo...om ), a drug development company commercializing t...on its Dynamic Cross Linking (DXL) technology, is ...nto a loan facility with a group of investors for ..., The loan facility, subject to final approval of ...
...sion Inc. ("Encision") (OTC Bulletin Board: ECIA),... technology that is emerging as a standard of care...n agreement with Caldera Medical, Inc. ("Caldera")...,s products include the Desara(R) Sling System for...imated to affect 15 million women in the U.S. Enc...
...FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics"...mpletion of patient enrolment in its U.K. clinical...avenous administration of REOLYSIN(R) in combinati...dvanced cancers including breast, and head and nec...ono of The Royal Marsden NHS Foundation Trust and ...
Other Biology Technology:InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million 2Encision Enters Into Sales Representation Agreement With Caldera Medical 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:11/9/2009)...wet ethanol production method that begins by soaki... in more gallons of ethanol and more usable co-pro...their buck by about 20 percent. , "The conventi...t other than distillers dried grains with soluble,...ersity of Illinois Agricultural Engineer Esha Khul...
(Date:11/9/2009)...hildren with cancer, the hopeful news is that pedi...cades. Among the bad newstreatments that enable su...ed with cancer who have reached puberty currently ...efore undergoing cancer treatment, they may have t...unger boys, however, do not produce sperm, althoug...
(Date:11/9/2009)...a. The U.S. Department of Energy (DOE) has announ...abama at Birmingham (UAB) School of Engineering on...s emissions through the capture and permanent safe...). The project is in collaboration with Southern C...unded by the DOE through the 2009 American Recover...
Breaking Biology News(10 mins):Wet ethanol production process yields more ethanol and more co-products 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 1Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 4New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 1New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 2Study demonstrates the anti inflammatory properties of pine bark extract 51856 1Study demonstrates the anti inflammatory properties of pine bark extract 51856 2
... first evidence that a group of proteins called ph...he nervous system, has been shown in fruit flies a...rnia, San Diego (UCSD) School of Medicine, in coll...a Jolla, California. The phosphatases are required...ncing expression of neuronal genes in non-nervous ...
...of 20 April, the Ministry of Health in Angola has ...Of these cases, 244 were fatal. In Uige Province, ...ases, of which 233 have been fatal, were reported ...e international response to the outbreak in Angola... Marburg haemorrhagic fever, and the conditions in...
...ng genetically altered zebrafish that glow in the ... new tools that shed light upon biological clock c...f biology and biochemistry at UH, and Maki Kaneko,...ty of California-San Diego, presented their findin...of Circadian Gene Expression in Transgenic Zebrafi...
Other Biology News:Marburg haemorrhagic fever in Angola update 2Marburg haemorrhagic fever in Angola update 3Glow-in-the-dark zebrafish at UH hold keys to biological clocks 2Glow-in-the-dark zebrafish at UH hold keys to biological clocks 3
MagCellect Rat CD4+ T Cell Isolation Kit from R&D Systems
Rabbit Anti-Human OLFM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-QUINOLINIC ACID Polyclonal Antibody, Unconjugated from AbD Serotec
Coverslips for Microarrays from GE Healthcare, formerly Amersham Biosciences
Biology Products: